Guggenheim on Avalo (AVTX): 'Phase II LOTUS Study Readout in HS Remains On-Track for 2Q26 (Likely in May, Per Our Est)'
Tweet Send to a Friend
Guggenheim analyst Yatin Suneja reiterated a Buy rating and $50.00 price target on Avalo Therapeutics Inc. (NASDAQ: AVTX).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
